Trial
NCT00742482
Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
LEO Pharma
Collaborators
—
Condition
Acute Lung Injury
Intervention
HL 10
Why stopped
A 300 patient safety analysis by the Data Monitoring Committee showed a trend towards higher mortality in the treatment group.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-24